Basimglurant is primarily investigated for its potential therapeutic applications in the field of neuroscience. It acts as a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5), which plays a significant role in regulating synaptic plasticity and neuronal communication. This mechanism makes it a promising candidate for treating central nervous system disorders, particularly major depressive disorder (MDD). Clinical studies have explored its efficacy in alleviating depressive symptoms, with a focus on its ability to modulate glutamate signaling, which is often dysregulated in depression. Additionally, basimglurant has been studied for its potential in addressing anxiety and other mood-related conditions. Its unique action on mGluR5 receptors offers a novel approach compared to traditional antidepressants, potentially providing benefits with fewer side effects. Research is ongoing to further evaluate its safety, efficacy, and broader applications in mental health disorders.